Global Conjugate Vaccine Market Professional Survey Report 2018

Table of Contents

Global Conjugate Vaccine Market Professional Survey Report 2017

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Conjugate Vaccine Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 Haemophilus B Market Performance (Volume)
  • 2.1.2 Monovalent Market Performance (Volume)
  • 2.1.3 Multivalent Market Performance (Volume)
  • 2.1.4 Others Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.1.1 Haemophilus B Market Performance (Value)
  • 2.1.2 Monovalent Market Performance (Value)
  • 2.1.3 Multivalent Market Performance (Value)
  • 2.1.4 Others Market Performance (Value)

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 Influenza Market Performance (Volume)
  • 3.1.2 Pneumococcal Market Performance (Volume)
  • 3.1.3 Meningococcal Market Performance (Volume)
  • 3.1.4 Others Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 Astellas Pharma Inc
  • 4.1.1 Astellas Pharma Inc Profiles
  • 4.1.2 Astellas Pharma Inc Product Information
  • 4.1.3 Astellas Pharma Inc Conjugate Vaccine Business Performance
  • 4.1.4 Astellas Pharma Inc Conjugate Vaccine Business Development and Market Status
• 4.2 CSL Limited
  • 4.2.1 CSL Limited Profiles
  • 4.2.2 CSL Limited Product Information
  • 4.2.3 CSL Limited Conjugate Vaccine Business Performance
  • 4.2.4 CSL Limited Conjugate Vaccine Business Development and Market Status
• 4.3 Emergent BioSolutions
  • 4.3.1 Emergent BioSolutions Profiles
  • 4.3.2 Emergent BioSolutions Product Information
  • 4.3.3 Emergent BioSolutions Conjugate Vaccine Business Performance
  • 4.3.4 Emergent BioSolutions Conjugate Vaccine Business Development and Market Status
• 4.4 GlaxoSmithKline
  • 4.4.1 GlaxoSmithKline Profiles
  • 4.4.2 GlaxoSmithKline Product Information
  • 4.4.3 GlaxoSmithKline Conjugate Vaccine Business Performance
  • 4.4.4 GlaxoSmithKline Conjugate Vaccine Business Development and Market Status
• 4.5 Johnson&Johnson
  • 4.5.1 Johnson&Johnson Profiles
  • 4.5.2 Johnson&Johnson Product Information
  • 4.5.3 Johnson&Johnson Conjugate Vaccine Business Performance
  • 4.5.4 Johnson&Johnson Conjugate Vaccine Business Development and Market Status
• 4.6 MedImmune
  • 4.6.1 MedImmune Profiles
  • 4.6.2 MedImmune Product Information
  • 4.6.3 MedImmune Conjugate Vaccine Business Performance
  • 4.6.4 MedImmune Conjugate Vaccine Business Development and Market Status
• 4.7 Merck
  • 4.7.1 Merck Profiles
  • 4.7.2 Merck Product Information
  • 4.7.3 Merck Conjugate Vaccine Business Performance
  • 4.7.4 Merck Conjugate Vaccine Business Development and Market Status
• 4.8 Pfizer
  • 4.8.1 Pfizer Profiles
  • 4.8.2 Pfizer Product Information
  • 4.8.3 Pfizer Conjugate Vaccine Business Performance
  • 4.8.4 Pfizer Conjugate Vaccine Business Development and Market Status
• 4.9 Sanofi Pasteur
  • 4.9.1 Sanofi Pasteur Profiles
  • 4.9.2 Sanofi Pasteur Product Information
  • 4.9.3 Sanofi Pasteur Conjugate Vaccine Business Performance
  • 4.9.4 Sanofi Pasteur Conjugate Vaccine Business Development and Market Status
• 4.10 Serum Institute
  • 4.10.1 Serum Institute Profiles
  • 4.10.2 Serum Institute Product Information
  • 4.10.3 Serum Institute Conjugate Vaccine Business Performance
  • 4.10.4 Serum Institute Conjugate Vaccine Business Development and Market Status
• 4.11 India Pvt

5 Market Performance for Manufacturers

• 5.1 Global Conjugate Vaccine Capacity (K Units) and Market Share by Manufacturers 2013-2018
• 5.2 Global Conjugate Vaccine Sales (K Units) and Market Share by Manufacturers 2013-2018
• 5.3 Global Conjugate Vaccine Revenue (M USD) and Market Share by Manufacturers 2013-2018
• 5.4 Global Conjugate Vaccine Price (USD/Unit) of Manufacturers 2013-2018
• 5.5 Global Conjugate Vaccine Gross Margin of Manufacturers 2013-2018
• 5.6 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 China Market Performance for Manufacturers
  • 6.1.1 China Conjugate Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.1.2 China Conjugate Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.1.3 China Conjugate Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.1.4 China Conjugate Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.1.5 Market Concentration
• 6.2 USA Market Performance for Manufacturers
  • 6.2.1 USA Conjugate Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.2.2 USA Conjugate Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.2.3 USA Conjugate Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.2.4 USA Conjugate Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.2.5 Market Concentration
• 6.3 Europe Market Performance for Manufacturers
  • 6.3.1 Europe Conjugate Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.3.2 Europe Conjugate Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.3.3 Europe Conjugate Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.3.4 Europe Conjugate Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.3.5 Market Concentration
• 6.4 Japan Market Performance for Manufacturers
  • 6.4.1 Japan Conjugate Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.4.2 Japan Conjugate Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.4.3 Japan Conjugate Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.4.4 Japan Conjugate Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.4.5 Market Concentration
• 6.5 Korea Market Performance for Manufacturers
  • 6.5.1 Korea Conjugate Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.5.2 Korea Conjugate Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.5.3 Korea Conjugate Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.5.4 Korea Conjugate Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.5.5 Market Concentration
• 6.6 India Market Performance for Manufacturers
  • 6.6.1 India Conjugate Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.6.2 India Conjugate Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.6.3 India Conjugate Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.6.4 India Conjugate Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.6.5 Market Concentration
• 6.7 Southeast Asia Market Performance for Manufacturers
  • 6.7.1 Southeast Asia Conjugate Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.7.2 Southeast Asia Conjugate Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.7.3 Southeast Asia Conjugate Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.7.4 Southeast Asia Conjugate Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.7.5 Market Concentration
• 6.8 South America Market Performance for Manufacturers
  • 6.8.1 South America Conjugate Vaccine Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.8.2 South America Conjugate Vaccine Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.8.3 South America Conjugate Vaccine Price (USD/Unit) of Manufacturers 2013-2018
  • 6.8.4 South America Conjugate Vaccine Gross Margin of Manufacturers 2013-2018
  • 6.8.5 Market Concentration

7 Global Conjugate Vaccine Market Performance (Sales Point)

• 7.1 Global Conjugate Vaccine Capacity (K Units) and Market Share by Regions 2013-2018
• 7.2 Global Conjugate Vaccine Sales (K Units) and Market Share by Regions 2013-2018
• 7.3 Global Conjugate Vaccine Revenue (M USD) and Market Share by Regions 2013-2018
• 7.4 Global Conjugate Vaccine Price (USD/Unit) by Regions 2013-2018
• 7.5 Global Conjugate Vaccine Gross Margin by Regions 2013-2018

8 Development Trend for Regions (Sales Point)

• 8.1 Global Conjugate Vaccine Capacity and Growth, Sales Value and Growth Rate2013-2018
• 8.2 China Conjugate Vaccine Capacity and Growth, Sales Value and Growth Rate2013-2018
• 8.3 USA Conjugate Vaccine Capacity and Growth, Sales Value and Growth Rate2013-2018
• 8.4 Europe Conjugate Vaccine Capacity and Growth, Sales Value and Growth Rate2013-2018
• 8.5 Japan Conjugate Vaccine Capacity and Growth, Sales Value and Growth Rate2013-2018
• 8.6 Korea Conjugate Vaccine Capacity and Growth, Sales Value and Growth Rate2013-2018
• 8.7 India Conjugate Vaccine Capacity and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Southeast Asia Conjugate Vaccine Capacity and Growth, Sales Value and Growth Rate2013-2018
• 8.9 Southeast Asia Conjugate Vaccine Capacity and Growth, Sales Value and Growth Rate2013-2018

9 Development Trend for Regions (Sales Point)

• 9.1 Global Conjugate Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 9.2 China Conjugate Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 9.3 USA Conjugate Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 9.4 Europe Conjugate Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 9.5 Japan Conjugate Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 9.6 Korea Conjugate Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 9.7 India Conjugate Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 9.8 Southeast Asia Conjugate Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018
• 9.9 South America Conjugate Vaccine Sales and Growth, Sales Value and Growth Rate2013-2018

10 Upstream Source, Technology and Cost

• 10.1 Upstream Source
• 10.2 Technology
• 10.3 Cost

11 Channel Analysis

• 11.1 Market Channel
• 11.2 Distributors

12 Consumer Analysis

• 12.1 Influenza Industry
• 12.2 Pneumococcal Industry
• 12.3 Meningococcal Industry

13 Market Forecast 2019-2024

• 13.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
  • 13.1.1 Global Conjugate Vaccine Capacity (K Units) and Share by Regions 2019-2024
  • 13.1.2 Global Conjugate Vaccine Capacity (K Units), Sales (K Units) and Growth Rate 2019-2024
  • 13.1.3 China Conjugate Vaccine Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.1.4 USA Conjugate Vaccine Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.1.5 Europe Conjugate Vaccine Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.1.6 Japan Conjugate Vaccine Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.1.7 Korea Conjugate Vaccine Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.1.8 India Conjugate Vaccine Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.1.9 Southeast Asia Conjugate Vaccine Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.1.10 South America Conjugate Vaccine Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 13.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
  • 13.3.1 Overall Market Performance
  • 13.3.2 Haemophilus B Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.3.3 Monovalent Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.3.4 Multivalent Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.3.5 Others Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 13.4 Sales by Application 2019-2024
  • 13.4.1 Overall Market Performance
  • 13.4.2 Influenza Sales and and Growth Rate 2019-2024
  • 13.4.3 Pneumococcal Sales and and Growth Rate 2019-2024
  • 13.4.4 Meningococcal Sales and and Growth Rate 2019-2024
  • 13.4.5 Others Sales and and Growth Rate 2019-2024
• 13.5 Price (USD/Unit) and Gross Profit
  • 13.5.1 Global Conjugate Vaccine Price (USD/Unit) Trend 2019-2024
  • 13.5.2 Global Conjugate Vaccine Gross Profit Trend 2019-2024

14 Conclusion